NASDAQ:EDIT Editas Medicine (EDIT) Stock Price, News & Analysis $2.56 +0.31 (+13.78%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$2.56 +0.00 (+0.20%) As of 05:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Editas Medicine Stock (NASDAQ:EDIT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Editas Medicine alerts:Sign Up Key Stats Today's Range$2.23▼$2.8850-Day Range$1.33▼$2.5652-Week Range$0.91▼$6.05Volume9.52 million shsAverage Volume2.59 million shsMarket Capitalization$214.30 millionP/E RatioN/ADividend YieldN/APrice Target$4.70Consensus RatingHold Company Overview Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Read More Editas Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreEDIT MarketRank™: Editas Medicine scored higher than 84% of companies evaluated by MarketBeat, and ranked 183rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingEditas Medicine has received a consensus rating of Hold. The company's average rating score is 2.31, and is based on 2 buy ratings, 7 hold ratings, and 2 sell ratings.Amount of Analyst CoverageEditas Medicine has only been the subject of 3 research reports in the past 90 days.Read more about Editas Medicine's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Editas Medicine are expected to grow in the coming year, from ($2.71) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Editas Medicine is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Editas Medicine is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEditas Medicine has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Editas Medicine's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.29% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEditas Medicine does not currently pay a dividend.Dividend GrowthEditas Medicine does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.05 Percentage of Shares Shorted10.29% of the float of Editas Medicine has been sold short.Short Interest Ratio / Days to CoverEditas Medicine has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Editas Medicine has recently decreased by 6.33%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News Sentiment0.66 News SentimentEditas Medicine has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Editas Medicine this week, compared to 5 articles on an average week.Search InterestOnly 11 people have searched for EDIT on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.MarketBeat Follows7 people have added Editas Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Editas Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,146.00 in company stock.Percentage Held by InsidersOnly 2.10% of the stock of Editas Medicine is held by insiders.Percentage Held by Institutions71.90% of the stock of Editas Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Editas Medicine's insider trading history. Receive EDIT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address EDIT Stock News HeadlinesEditas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in StockJune 5, 2025 | insidertrades.comEditas Medicine Inc EDIT Company Vitals - U.S. NewsJuly 1 at 10:11 PM | money.usnews.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move. | Porter & Company (Ad)Sickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsightJuly 1 at 10:11 PM | theglobeandmail.comWall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to "Hold"June 29, 2025 | americanbankingnews.comWall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?June 28, 2025 | fool.comEditas Medicine Inc. Annual Cash Flow Statement - MarketWatchJune 25, 2025 | marketwatch.comEditas Medicine Inc.June 25, 2025 | barrons.comSee More Headlines EDIT Stock Analysis - Frequently Asked Questions How have EDIT shares performed this year? Editas Medicine's stock was trading at $1.27 at the beginning of 2025. Since then, EDIT stock has increased by 101.6% and is now trading at $2.56. View the best growth stocks for 2025 here. How were Editas Medicine's earnings last quarter? Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Monday, May, 12th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.08. The company had revenue of $4.66 million for the quarter, compared to the consensus estimate of $0.79 million. Editas Medicine had a negative trailing twelve-month return on equity of 139.24% and a negative net margin of 701.06%. When did Editas Medicine IPO? Editas Medicine (EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers. How do I buy shares of Editas Medicine? Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Editas Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Editas Medicine investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Tesla (TSLA), Enovix (ENVX) and Luminar Technologies (LAZR). Company Calendar Last Earnings5/12/2025Today7/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EDIT CIK1650664 Webwww.editasmedicine.com Phone(617) 401-9000FaxN/AEmployees230Year FoundedN/APrice Target and Rating Average Stock Price Target$4.70 High Stock Price Target$12.00 Low Stock Price Target$1.00 Potential Upside/Downside+83.6%Consensus RatingHold Rating Score (0-4)2.31 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$237.09 million Net Margins-701.06% Pretax Margin-701.06% Return on Equity-139.24% Return on Assets-63.87% Debt Debt-to-Equity RatioN/A Current Ratio3.08 Quick Ratio3.08 Sales & Book Value Annual Sales$32.31 million Price / Sales6.63 Cash FlowN/A Price / Cash FlowN/A Book Value$1.63 per share Price / Book1.57Miscellaneous Outstanding Shares83,710,000Free Float81,955,000Market Cap$214.30 million OptionableOptionable Beta2.15 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:EDIT) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Editas Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Editas Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.